-
Mashup Score: 51The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023 - 5 month(s) ago
This commentary summarizes the most important emerging areas of kidney cancer research discussed and debated among the stakeholders at the 5th Kidney Cancer Res
Source: academic.oup.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Belzutifan Improves PFS in Pretreated Advanced RCC - 9 month(s) ago
Treatment with belzutifan demonstrated a statistically significant and clinically meaningful improvement in progression-free survivalcompared with everolimus in patients with advanced renal cell carcinoma that has progressed on prior PD-1/PD-L1 and VEGF inhibitors, in sequence or in combination.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Treatment with belzutifan demonstrated a statistically significant improvement in PFS compared with everolimus in patients with advanced RCC that has progressed on prior PD-1/PD-L1 and VEGF inhibitors. @kidneycan #KCRS23 #kcsm https://t.co/CN5LH2FQLO
-
-
Mashup Score: 10Home - 9 month(s) ago
KidneyCAN works to accelerate cures for kidney cancer through legislative advocacy, research collaboration, and patient education.
Source: kidneycan.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
The 2023 Kidney Cancer Research Summit #KCRS23 Abstracts were just published in @OncJournal @kidneycan @OncoAlert @advocatekidneys @CDMRP https://t.co/mS7Djo5BAD https://t.co/FpC3WVY3pm
-
-
Mashup Score: 1Belzutifan Improves PFS in Pretreated Advanced RCC - 9 month(s) ago
Treatment with belzutifan demonstrated a statistically significant and clinically meaningful improvement in progression-free survivalcompared with everolimus in patients with advanced renal cell carcinoma that has progressed on prior PD-1/PD-L1 and VEGF inhibitors, in sequence or in combination.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In addition to meeting the co-primary end point of improved PFS in the phase 3 LITESPARK-005 trial, belzutifan also significantly improved ORR vs everolimus, meeting a key secondary end point. @kidneycan #KCRS23 #kcsm https://t.co/gEirjNeRor https://t.co/XukvMtmYTU
-
-
Mashup Score: 0ORCHID Trial of Olaparib Monotherapy Could Lay Groundwork for Investigating PARP Inhibitors in Advanced RCC - 9 month(s) ago
Yasser Mohamed Ali Ged, MBBS, highlights the early efficacy seen in patients with renal cell carcinoma with BAP1 mutations and next steps for the ORCHID trial.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Yasser Mohamed Ali Ged, MBBS, highlights the early efficacy seen in patients with RCC with BAP1 mutations and next steps for the ORCHID trial. @HopkinsMedicine @kidneycan #KCRS23 #kcsm https://t.co/IPn1erTRxm
-
-
Mashup Score: 0SAMETA Trial Evaluates Efficacy of Savolitinib Plus Durvalumab in MET-Driven Papillary RCC - 9 month(s) ago
The safety and efficacy achieved with the combination of savolitinib and durvalumab vs standard-of-care sunitinib or durvalumab monotherapy will be evaluated in patients with MET-driven papillary renal cell carcinoma in the phase 3 SAMETA trial.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The phase 3 SAMETA study of savolitinib and durvalumab is enrolling patients 18 years of age or older with unresectable and locally advanced or metastatic PRCC @DrChoueiri @DanaFarberNews @harvardmed @kidneycan #KCRS23 #kcsm https://t.co/szHBges9sV https://t.co/2cQQZvoKLO
-
-
Mashup Score: 1Belzutifan Improves PFS in Pretreated Advanced RCC - 9 month(s) ago
Treatment with belzutifan demonstrated a statistically significant and clinically meaningful improvement in progression-free survivalcompared with everolimus in patients with advanced renal cell carcinoma that has progressed on prior PD-1/PD-L1 and VEGF inhibitors, in sequence or in combination.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Belzutifan Improves PFS in Pretreated Advanced RCC @kidneycan #KCRS23 #kcsm https://t.co/Fai2a32QMv
-
-
Mashup Score: 0LITESPARK-024 Trial to Examine HIF-2α and CDK4/6 Inhibition With Belzutifan Plus Palbociclib in Advanced RCC - 9 month(s) ago
David F. McDermott, MD, discusses how combining HIF-2α inhibition with CDK4/6 inhibition could be an effective treatment regimen in patients with renal cell carcinoma and shared details from the LITESPARK-024 trial.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The combination of belzutifan and palbociclib makes for an ideal pairing, given the tolerability of belzutifan and preclinical data showing potential activity with the 2 treatment classes in RCC. @harvardmed @kidneycan #KCRS23 #kcsm https://t.co/wWZFBoyvvh https://t.co/DqqNnfNEuU
-
-
Mashup Score: 0ORCHID Trial of Olaparib Monotherapy Could Lay Groundwork for Investigating PARP Inhibitors in Advanced RCC - 9 month(s) ago
Yasser Mohamed Ali Ged, MBBS, highlights the early efficacy seen in patients with renal cell carcinoma with BAP1 mutations and next steps for the ORCHID trial.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The efficacy produced by olaparib monotherapy in the phase 2 ORCHID trial could inform investigations of PARP inhibitor–based regimens for patients with RCC harboring BAP1 or DDR mutations. @HopkinsMedicine @kidneycan #KCRS23 #kcsm https://t.co/EkSpJDaeUO https://t.co/UyMhy1KKrS
-
-
Mashup Score: 1SAMETA Trial Evaluates Efficacy of Savolitinib Plus Durvalumab in MET-Driven Papillary RCC - 9 month(s) ago
The safety and efficacy achieved with the combination of savolitinib and durvalumab vs standard-of-care sunitinib or durvalumab monotherapy will be evaluated in patients with MET-driven papillary renal cell carcinoma in the phase 3 SAMETA trial.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The safety and efficacy of savolitinib and durvalumab vs sunitinib or durvalumab alone will be evaluated in patients with MET-driven papillary RCC in the SAMETA trial. @DrChoueiri @DanaFarberNews @harvardmed @kidneycan #KCRS23 #kcsm https://t.co/SUmEqdRidP
-
The White paper #KCRS23 is online in @OncJournal: Sessions covered tumor metabolism, novel immune pathways, trials, immunotherapy, + progress in biomarkers! @kidneycan @OncoAlert @HHammersMD @montypal @advocatekidneys @kcpels @DanaFarber_GU @KCPUTSW https://t.co/J7BF9vfXUn https://t.co/N3EQ6BPrb8